Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe
Abstract: Patient-reported outcomes (PROs) give direct insights into the treatment’s impact on patient’s life and complement clinical outcomes. However, since the advent of chimeric antigen receptor T-cell therapy (CAR-T), PROs have been underreported. Particularly, little is known about long-term h...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Elsevier
2025-12-01
|
| Rangatū: | Blood Advances |
| Urunga tuihono: | http://www.sciencedirect.com/science/article/pii/S2473952925005889 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
